Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
13 November 2023 - 10:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
Notification of Late Filing
Commission File Number:
333-22261
(Check One): ☐ Form 10-K ☐ Form
20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form
N-SAR
For
Period Ended: September 30, 2023
|
☐ |
Transition Report on Form 10-K |
|
☐ |
Transition Report on Form 20-F |
|
☐ |
Transition Report on Form 11-K |
|
☐ |
Transition Report on Form 10-Q |
|
☐ |
Transition Report on Form N-SAR |
For the Transition Period Ended:
Nothing in this form shall be construed to imply
that the Commission has verified any information contained herein.
If the notification relates to a portion of the
filing checked above, identify the Item(s) to which the notification relates:
Part I - Registrant Information
Soul
Biotechnology Corp
Full Name of Registrant |
|
Former Name if Applicable |
36
Fourth Ave. N. |
Address of Principal Executive Office (Street and Number) |
Yorkton Saskatchewan, Canada S3N 2V7 |
City, State and Zip Code |
Part II - Rules 12b-25(b) and (c)
If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-(b), the following should be completed. (Check box,
if appropriate)
| ☒ | (a) The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable effort or expense; |
| ☒ | (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, 11-K or Form N- SAR, or portion thereof will be filed on or before the fifteenth calendar day following
the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before
the fifth calendar day following the prescribed due date; and |
| ☐ | (c) The accountant’s statement or other exhibit required
by Rule 12b-25(c) has been attached if applicable. |
Part III - Narrative
State below in reasonable detail the reasons why
Form 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof could not be file within the prescribed period.
The Company was unable to compile the necessary
financial information required to prepare a complete filing. Thus, the Company would be unable to file the periodic report in a timely
manner without unreasonable effort or expense. The Company expects to file within the extension period.
Part IV - Other Information
| (1) | Name and telephone number of person to contract in regard to
this notification. |
Rachael Martinuik |
|
(306) |
|
563-4123 |
(Name) |
|
(Area Code) |
|
(Telephone Number) |
| (2) | Have all other periodic reports required under section 13 or
15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for
such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☒ Yes ☐ No |
| (3) | Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the
subject report or portion thereof? ☐ Yes ☒ No |
If so: attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.
Soul Biotechnology Corp
(Name of Registrant as specified in charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date:
November 13, 2023 |
By: |
/s/
Rachel Martinuik |
|
|
Rachel Martinuik
|
|
|
Its: |
Chief Executive Officer |
Adorbs (CE) (USOTC:ADOB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Adorbs (CE) (USOTC:ADOB)
Historical Stock Chart
From Dec 2023 to Dec 2024